Clinical Trial Search

Primary: Percentage of Participants With Booster Response in Terms of Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titer Levels at 1 Month After Booster Vaccination…

Primary: Radiological Progression Free Survival (rPFS) by Blinded Independent Central Review (BICR) - Cohort A Only — 7.39; 3.55 Months — p=<0.0001

Primary: Number of Participants With Total Protection in the Acute, Delayed and Overall Periods — 22; 14; 11; 5 Participants

Primary: Change in Absolute FEV1 From Baseline Over 26 Weeks — 106.53; 52.38 mL — p=0.059

Primary: Number of Patients With Early Clinical Improvement — 111; 80 Participants — p=<0.03

Primary: Migraine Headache Days — 7.12; 6.92; 5.53; 4.79 Days

Primary: Progression Free Survival (PFS) as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) — 5.2; 7.7 Months — p=<0.0001

Primary: Percentage of Participants Who Are YF and Dengue Virus (DENV)-Naive at Baseline and Are Seroprotected Against YF on Day 30 as Measured by Plaque Reduction Neutralization…

Primary: 2-level Composite Responders for the Target Buttock — 16; 4; 194; 209 Participants — p=0.006

Primary: Waist Circumference at Week 12. — 97.6; 97.2 centimeters — p=<0.001

Primary: Change in # of Mean Nocturic Episodes Per Night — -1.4; -1.4; -1.6; -1.2 nocturic episodes per night

Primary: Overall Response Rate (ORR) at Week 28 — 66.3; 70.6 percentage of participants

Primary: 60-day Mortality — 50; 47; 227; 239 Participants — p=0.635

Primary: Number of Participants Reporting Adverse Events — 138; 151; 110; 62 Participants

Primary: 2-level Composite Responders for the Target Buttock — 12; 1; 202; 205 Participants — p=0.002